Sir, Metastatic prostatic adenocarcinoma to the orbit diagnosed by prostate-specific antigen staining Although bone is the most common metastatic site, orbital metastases from prostatic carcinoma have been reported. [1] [2] [3] [4] [5] We report a prostate-specific antigen (PSA) stained orbital metastasis developing from an occult prostate adenocarcinoma.
Case report
A 72-year-old man was referred to us in February 2002 with a progressive enlarged mass in the left orbit ( Figure 1 ). Examination revealed visual acuity correctable to 6/6 OU. Hertel measurements were 15 mm OD and 18 mm OS, and a base of 104 mm. Ocular motility in the left eye was mildly restricted in downgaze. Anterior and posterior segment examinations and intraocular pressures were normal.
Computed tomography (CT) demonstrated soft tissue infiltration in the inferomedial left orbit (Figure 1 ). Incisional biopsy showed poorly differentiated adenocarcinoma. Systematic evaluations revealed an enlarged prostate and abnormal serum PSA (8.3 ng/ml). Transrectal ultrasound-guided (TRUS) biopsy of prostate showed benign prostate hyperplasia. Because extensive systemic evaluation failed to detect evidence of any other concurrent tumour, orbital exenteration was performed. Microscopically, the specimens showed a poorly differentiated adenocarcinoma with tumour emboli in the vessels (Figure 2 ). Immunoperoxidase stains were positive for CK7, PSA, and prostate acid phosphatase (Figure 2 ). The patient received adjunct radiotherapy for 5 weeks (total dose of 50 Gy over 25 fractions) with no radiationrelated side effect. During the 4-year followup period, the serum PSA ranged between 8.30 and 9.37 ng/ml, and repeat TRUS biopsy and transurethral resection of prostate (TURP) showed benign prostatic hyperplasia. TRUS biopsy was performed again in May 2006, which revealed adenocarcinoma (Gleason's score 3 þ 3). Pelvic CT and bone scan was unremarkable. He was transferred for adjunct radiotherapy (78 Gy). No tumour recurrence was noted after 1 year.
Comment
The current case is unique in that orbital metastasis might have occurred from an occult prostate adenocarcinoma, which was hardly detected. In Shields' series, the primary tumour remained obscure despite systemic evaluation in 10% of metastatic orbital tumours. 6 In the current case, immunoperoxidase stains for PSA in orbital lesions and abnormal serum PSA provide us a hint to make an effort to explore the primary prostate carcinoma by thorough evaluations and repeat biopsies. Although the survival rate for patients with metastatic prostate cancer at diagnosis is relatively poor (median survival was 2.5 years), 7 timely intervention based on early diagnosis may improve their prognosis.
In conclusion, a PSA immunoperoxidase stain should be performed in all men with orbital adenocarcinoma of unknown primary site. Careful and long-term follow-up is mandatory for these patients, because the orbital focus may originate from an occult prostate adenocarcinoma, which is hardly to be detected early. 
